Q: Doripenem is highly effective among all carbapenems in ventilator-associated pneumonia (VAP)?
Doripenem became popular for VAP as they were found to be more potent in vitro against P. aeruginosa. But subsequent follow-up study showed increased 28-days mortality in VAP patients. In fact, the study was stopped early. This leads FDA to add a warning on Doripenem for use in VAP patients.
References:1. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16:R218.